Valuation: KDventures AB

Market Cap 160M 16.77M 14.53M 13.61M 12.42M 23.36M 1.6B 23.76M 62.51M 801M 62.97M 61.6M 2.67B P/E 2024
-31.7x
P/E 2025 -0.61x
Enterprise Value 137M 14.38M 12.46M 11.66M 10.64M 20.03M 1.37B 20.36M 53.58M 686M 53.98M 52.8M 2.29B EV / Sales 2024
118x
EV / Sales 2025 56.8x
Free-Float
65.1%
Yield 2024 *
-
Yield 2025 -
1 day+1.24%
1 week+0.41%
Current month+0.62%
1 month-2.00%
3 months-19.54%
6 months-16.67%
Current year-43.81%
1 week 0.24
Extreme 0.238
0.25
1 month 0.24
Extreme 0.238
0.26
Current year 0.2
Extreme 0.2
0.45
1 year 0.2
Extreme 0.2
1.1
3 years 0.2
Extreme 0.2
1.95
5 years 0.2
Extreme 0.2
11.24
10 years 0.2
Extreme 0.2
11.24
Manager TitleAgeSince
Chief Executive Officer 61 31/05/2017
Director of Finance/CFO 58 30/09/2022
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 33 27/11/2017
Director/Board Member 57 18/02/2021
Chairman 50 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
27/03/23 Buy

General Counsel

50,000 0.0187%
30/09/22 Buy

General Counsel

40,187 0.0150%
08/03/22 Buy

Chairman

64,001 0.0367%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+0.41%-76.35%-84.80% 16.81M
+0.95%+3.79%-16.67%+3.94% 188B
+0.81%+4.48%-2.89%+7.92% 114B
+1.66%+7.75%+13.52%+76.13% 62.02B
+2.38%+3.92%+35.52%+60.21% 55.26B
+0.80%+6.24%-6.11%-35.98% 48.93B
+1.11%+1.63%+13.50%-20.89% 33.08B
+3.68%-16.86% - - 29.66B
+0.10%+1.03%+46.61%-10.74% 24.78B
+8.53%+11.42%-5.85%+18.17% 23.91B
Average +2.11%+2,937.26%+0.14%+1.55% 58.01B
Weighted average by Cap. +1.53%+2,681.66%+0.91%+13.47%

Financials

2024 2025
Net sales 1.84M 193K 167K 157K 143K 269K 18.43M 274K 720K 9.22M 725K 710K 30.77M 1.67M 176K 152K 143K 130K 245K 16.75M 249K 655K 8.39M 660K 645K 27.98M
Net income -8.1M -852K -738K -691K -630K -1.19M -81.22M -1.21M -3.17M -40.66M -3.2M -3.13M -136M -194M -20.38M -17.66M -16.53M -15.09M -28.39M -1.94B -28.86M -75.95M -973M -76.52M -74.85M -3.25B
Net Debt -39.9M -4.19M -3.63M -3.4M -3.1M -5.84M -400M -5.94M -15.63M -200M -15.75M -15.4M -668M -22.8M -2.4M -2.08M -1.94M -1.77M -3.34M -229M -3.39M -8.93M -114M -9M -8.8M -382M
Logo KDventures AB
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Employees
7
Date Price Change Volume
11/08/26 SEK 0.2450 +1.24% 132,163
10/08/26 SEK 0.2420 -0.62% 263,201
07/08/26 SEK 0.2435 +1.67% 608,305
06/08/26 SEK 0.2395 -1.03% 615,927
05/08/26 SEK 0.2420 -0.82% 250,499

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KDV B Stock